Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2009
10/14/2009CN100548301C Injection for curing diarrhea of pig and preparation thereof
10/14/2009CN100548300C Use of ranolazine for the preparation of a medicament for the treatment of arrhythmias
10/14/2009CN100548299C Excitatory amino acid receptor antagonists
10/14/2009CN100548298C Pantoprazole sodium liposomes freeze-dry preparations and method of preparing the same
10/14/2009CN100548297C Slow release drop pills comprising toraesmide active ingredient and method for preparing same
10/14/2009CN100548296C Mitotic kinesin inhibitors
10/14/2009CN100548295C Aztreonam liposomes freeze-dry preparations and method of preparing the same
10/14/2009CN100548294C Use of compound in preparing medicine for enhancement of bone growth and inhibition of bone resorption
10/14/2009CN100548293C Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure
10/14/2009CN100548292C A micro-emulsion containing Vitamin C and Vitamin E
10/14/2009CN100548291C MCH antagonists for the treatment of obesity
10/14/2009CN100548290C Use of sulfamate derivative for treating impulse control disorders
10/14/2009CN100548289C Anthranilic acid amides and the derivatives thereof as cosmetic and pharmaceutical agents
10/14/2009CN100548288C Memory fixation accelerator
10/14/2009CN100548287C Percutaneous absorption preparation
10/14/2009CN100548286C A solid dispersion of ambroxol hydrochloride and composition thereof
10/14/2009CN100548285C Terbinafine nano milk antifungal medicine and its preparation
10/14/2009CN100548284C Microemulsion of hypocrellin, and its preparing method
10/14/2009CN100548283C Prevention and treatment of androgen-deprivation induced osteoporosis
10/14/2009CN100548279C Delayed total release gastrointestinal drug delivery system
10/14/2009CN100548278C New preparation method for raising rate of packaging microspheres of naltrexone
10/14/2009CN100548277C Preparing method of powder agglomerates
10/14/2009CN100548276C Melt-formulated, multi-particulate oral dosage form
10/14/2009CN100548274C Water type injection containing paclitaxel and its preparing method
10/14/2009CN100548271C Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
10/14/2009CN100548228C Composition and apparatus for transdermal delivery
10/14/2009CN100548157C Compositions comprising milk protein concentrate and fatty acid and processes of their preparation
10/14/2009CN100548144C Animal beverage
10/13/2009US7601882 Carrier for additive in an absorbent article
10/13/2009US7601876 Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis
10/13/2009US7601872 Cationic lipids capable of facilitating transport of biologically active agents or substances into cells; lipid aggregate macromolecular complex interacts with cells making the polyanionic macromolecule available for absorption and uptake by the cell
10/13/2009US7601870 Substituted aniline derivatives
10/13/2009US7601868 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity
10/13/2009US7601854 Diterpenes from the fruiting body of Antrodia camphorata and pharmaceutical compositions thereof
10/13/2009US7601850 less hypercalcemic than 1a,25 dihydroxy vitamin D3; bone disorders, psoriasis
10/13/2009US7601846 Such as 2-(2-Imino-benzothiazol-3-yl)-1-(4-pyrrolidin-1-yl-phenyl)-ethanone hydrobromide salt, for protecting mammalian cells from damaging effects of chemotherapy, irradiation
10/13/2009US7601844 Piperidinyl derivatives as modulators of chemokine receptor activity
10/13/2009US7601843 4-(2-furoyl)aminopiperidine compound useful as therapeutic agent for itching
10/13/2009US7601841 Quinolinyl and benzothiazolyl modulators
10/13/2009US7601840 Carboline derivatives useful in the inhibition of angiogenesis
10/13/2009US7601839 Pyrrolo-pyridine kinase modulators
10/13/2009US7601838 2[-2,5 dichlorobenzenesulfonyl]-1,2,3,4,-tetrahydro-9H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester; for intravascular thrombosis such as myocardial ischemia and stroke
10/13/2009US7601837 Quinoline derivatives and their use as 5-HT6 ligands
10/13/2009US7601836 Pyrido[2,3-D]pyrimidine inhibitors of phosphodiesterase (PDE) 7
10/13/2009US7601834 Methotrexate orotate; improve bioavailability and drug clearance thereby reducing toxicity in cancer patients and in non-infectious, non-neoplastic inflammatory conditions such as rheumatoid arthritis, psoriasis, systemic lupus, and multiple sclerosis
10/13/2009US7601758 Methods for concomitant administration of colchicine and macrolide antibiotics in the treatment of gout flares
10/13/2009US7601757 Containing specific ratios of omega-3, omega-6, and omega-9 fatty acids; provides optimized ratio of essential and nonessential fatty acids that can improve glucose tolerance of glucose intolerant individual, improve insulin sensitivity of insulin resistant individual, and reduce risk of vascular disease
10/13/2009US7601756 Method of treatment for irritable bowel syndrome
10/13/2009US7601754 7-Ethyl-3-hydoxy-2-(3,4,5-trihydoxy-phenyl)-chromen-4-one, for example; exhibits anti-oxidative properties in biological systems; utility in a sunscreen or skincare composition or to treat conditions involving oxidative damage, especially curative or prophylactic treatment of Alzheimer's disease
10/13/2009US7601753 Pyrrolidine melanocortin-specific compounds
10/13/2009US7601752 Pyrrolidine derivatives
10/13/2009US7601751 N-(4-{N'-[2-(6-Bromo-1H-indol-3-yl)-acetyl]-guanidinomethyl}-2,6-dichloro-phenyl)-acetamide, for example; useful in the treatment of neurological disorders related to beta-amyloid production, particularly, treatment of Alzheimer's Disease and similar diseases
10/13/2009US7601750 Hydroxyalkylindole derivatives as anticancer agents; methyl [3-hydroxymethyl-2-(1-pentyl)-1-(2-phenylethyl)-5-methyl]indole-6-carboxylate, for example
10/13/2009US7601749 Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof
10/13/2009US7601748 Anti-androgenic pyrrolidines with tumor-inhibiting action
10/13/2009US7601747 Reacting a nitrile with inorganic azide and divalent zinc salt in first solvent, cooling to room temperature, purifying di-tetrazole product by recrystallization in second solvent, and reacting purified di-tetrazole with a third solvent, a soluble reversible or non-reversible base, and 2-chloro-ethanol
10/13/2009US7601746 Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid
10/13/2009US7601745 Nuclear factor kappa beta (NF-kB) inhibitors such as [4-(1H-Indol-3-yl)-piperidin-1-yl]-{2-[1-(pyrazine-2-carbonyl)-piperidin-4-yl]-thiazol-4-yl}-methanone
10/13/2009US7601744 3-[3-(4-chlorophenyl)-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-N-methyl-3-phenylpropan-1-amine; antidepressants; analgesics
10/13/2009US7601743 controlling insects or representatives of the order Acarina
10/13/2009US7601742 Pyrrolidones with anti-HIV activity
10/13/2009US7601741 decyclization of {3-[(E)-2(7-chloro-2-quinolinyl)vinyl]phenyl}-4,5-dihydro-3H-benzo[c]thiepin-1-one by methylmagnesium halide with following conversion to montelukast
10/13/2009US7601740 urea substituted piperidine derivatives; may confer antipsychotic and anti-dyskinetic efficacy in humans; use as novel therapeutics, sometimes in conjunction with other therapeutics, for Parkinson's Disease, related human neurodegenerative diseases, and psychosis
10/13/2009US7601739 Treatment of breast cancer and osteoporosis
10/13/2009US7601738 Excitatory amino acid receptor antagonists
10/13/2009US7601737 Isotopically substituted proton pump inhibitors
10/13/2009US7601736 Pyridine derivatives, a process for their preparation and a pharmaceutical composition containing the same
10/13/2009US7601735 Antiviral compounds
10/13/2009US7601734 Cyclic amine compound
10/13/2009US7601733 5(S)-(2′-hydroxyethoxy)-20(S)-camptothecin and its preparation and use for the treatment of cancer
10/13/2009US7601732 Anticancer agents; 5(R)-(2''-hydroxyethoxy)-20(S)-camptothecin; X-ray powder diffraction
10/13/2009US7601731 Antimicrobial flush solutions
10/13/2009US7601730 Carboxylic acid derivatives, their preparation and use
10/13/2009US7601729 Matrix metalloproteinase inhibitors
10/13/2009US7601728 Bicyclic pyrrole derivatives
10/13/2009US7601727 Such as 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile; janus kinase 3 inhibitors; immunosuppressive agents; asthma
10/13/2009US7601726 Substituted pyrazolo[3,4-d]pyrimidines as p38 MAP kinase inhibitors
10/13/2009US7601725 Such as 1-[3-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-5-fluoro-phenyl]-3-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)-ethyl]-thiazol-2-yl}-urea
10/13/2009US7601724 Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
10/13/2009US7601723 For treating asthma and improving insulin sensitivity
10/13/2009US7601722 Gastrointestinal disorders; psychological disorders; neuropathic pain; cpgnition activators ; sexual disorders; chronic fatigue syndrome; sleep disorders; hyperactivity
10/13/2009US7601721 Substituted heterocyclic compounds
10/13/2009US7601720 especially dimethylphenylpiperazinium; treating a variety of pulmonary diseases with fewer side effects than other anti-inflammatory drugs, such as steroids
10/13/2009US7601719 Compounds, methods and pharmaceutical compositions for inhibiting PARP
10/13/2009US7601718 1,5-Dihydro-pyrazolo[4,3-c]pyridazin-6-one derivatives; glycogen synthase kinase-3 (CSK) inhibitors; nervous system, psychological, and neurodegenerative disorders; diabetes, psychiatry, multiple sclerosis (MS), myocardial infarction, reperfusion/ischemia, alopecia, and stroke
10/13/2009US7601717 Pterin analogs
10/13/2009US7601716 Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
10/13/2009US7601715 HIV inhibitors
10/13/2009US7601714 Pyrimidine derivatives useful as inhibitors of PKC-theta
10/13/2009US7601713 Kinase inhibitors and their uses
10/13/2009US7601712 Such as (1)-2-(4-chloro-3-((2-chloro-4-(((2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-ly)methoxy)benzoyl)amino)phenyl)-2-methylpropanoic acid; prostaglandin receptor agonists
10/13/2009US7601711 Such as [5-(4-cyclopentyl-piperazine-1-carbonyl)-1H-indol-2-yl]-morpholin-4-yl-methanone; histamine H3-antagonists
10/13/2009US7601709 Macrocyclic hepatitis C serine protease inhibitors
10/13/2009US7601708 Providing sustained systemic concentrations of therapeutic or prophylactic agents such as gamma-aminobutyric acid derivatives following oral adiminstration to animals
10/13/2009US7601707 Method for instantly relieving tissue inflammation
10/13/2009US7601706 Bile-acid conjugates providing for sustained systemic concentration of drugs
10/13/2009US7601705 Polymer controlled induced viscosity fiber system and uses thereof
10/13/2009US7601704 Process for synthesizing oil and surfactant-free hyaluronic acid nanoparticles and microparticles
10/13/2009US7601703 Complexing the target cell with therapeutic agent; antiproliferative agent
10/13/2009US7601702 Dutpase Inhibitors
1 ... 2541 2542 2543 2544 2545 2546 2547 2548 2549 2550 2551 2552 2553 2554 2555 2556 2557 2558 2559 2560 2561 ... 7860